ストックスクリーナーアプリを入手
70.31
4.47%
3.01
前日終値:
$67.30
開ける：
$67.71
24時間の取引高:
2.84M
Relative Volume:
1.28
時価総額：
$8.27B
収益：
$947.36M
当期純損益:
$392.47M
株価収益率:
23.28
EPS:
3.02
ネットキャッシュフロー:
$392.71M
1週間 パフォーマンス:
+2.09%
1か月 パフォーマンス:
+5.67%
6か月 パフォーマンス:
+30.59%
1年 パフォーマンス:
+46.45%
1日の値動き範囲:
$67.16
$70.35
1週間の範囲:
$67.02
$70.35
52週間の値動き範囲:
$47.50
$79.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
名前
Halozyme Therapeutics Inc
セクター
電話
(858) 794-8889
住所
12390 EL CAMINO REAL, SAN DIEGO, CA
HALO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
70.31 | 7.91B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-04 | ダウングレード | Goldman | Neutral → Sell |
| 2025-10-14 | アップグレード | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | 再開されました | Goldman | Neutral |
| 2025-05-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | ダウングレード | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-06-07 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 開始されました | TD Cowen | Outperform |
| 2023-07-24 | ダウングレード | Goldman | Buy → Neutral |
| 2023-07-24 | 開始されました | H.C. Wainwright | Buy |
| 2023-05-10 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 再開されました | Berenberg | Buy |
| 2023-03-16 | ダウングレード | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 再開されました | Morgan Stanley | Overweight |
| 2022-11-28 | 開始されました | Wells Fargo | Overweight |
| 2022-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2021-06-14 | 開始されました | Evercore ISI | Outperform |
| 2021-05-17 | 開始されました | SVB Leerink | Outperform |
| 2021-05-11 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 繰り返されました | The Benchmark Company | Buy |
| 2020-12-17 | 開始されました | Berenberg | Buy |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-07-01 | 開始されました | The Benchmark Company | Buy |
| 2020-02-05 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 開始されました | Goldman | Buy |
| 2019-11-05 | アップグレード | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 再開されました | Piper Jaffray | Neutral |
| 2018-05-11 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 開始されました | Goldman | Neutral |
| 2017-10-16 | 繰り返されました | Piper Jaffray | Overweight |
| 2017-01-06 | ダウングレード | Citigroup | Buy → Neutral |
| 2016-11-03 | 開始されました | Deutsche Bank | Buy |
| 2015-12-04 | 開始されました | Wells Fargo | Outperform |
| 2015-11-18 | 開始されました | Citigroup | Buy |
| 2015-09-22 | 開始されました | Barclays | Overweight |
| 2015-06-22 | 繰り返されました | JP Morgan | Overweight |
| 2015-03-03 | 繰り返されました | UBS | Buy |
| 2015-02-18 | 繰り返されました | MLV & Co | Buy |
| 2015-01-08 | 繰り返されました | MLV & Co | Buy |
すべてを表示
Halozyme Therapeutics Inc (HALO) 最新ニュース
Valuation Update: Why Halozyme Therapeutics Inc RV7 stock is a must watch tickerJuly 2025 Rallies & Low Drawdown Trading Techniques - moha.gov.vn
Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025 - The Globe and Mail
How Halozyme Therapeutics Inc. (HALO) Affects Rotational Strategy Timing - Stock Traders Daily
Here's What Analysts Think About Halozyme Therapeutics (HALO) - Finviz
Here’s What Analysts Think About Halozyme Therapeutics (HALO) - Insider Monkey
Market Still Lacking Some Conviction On Halozyme Therapeutics, Inc. (NASDAQ:HALO) - 富途牛牛
Halozyme Therapeutics (NASDAQ:HALO) Nasdaq Composite Biopharma Platform - Kalkine Media
Zacks Research Brokers Increase Earnings Estimates for HALO - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of "Hold" by Brokerages - MarketBeat
Shaker Investments LLC OH Decreases Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Voya Investment Management LLC Has $3.39 Million Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Pacer Advisors Inc. Acquires 456,649 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Osaic Holdings Inc. Grows Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Hedge Fund and Insider Trading News: Steve Cohen, Ray Dalio, Warren Buffett, Alan Howard, Scott Bessent, Saba Capital Management, Halozyme Therapeutics Inc (HALO), Epsilon Energy Ltd (EPSN), and More - Insider Monkey
Halozyme Therapeutics CEO sells $1.14 million in stock - Investing.com
Halozyme Therapeutics Stock Sees Relative Strength Rating - Investor's Business Daily
27,468 Shares in Halozyme Therapeutics, Inc. $HALO Acquired by Monument Capital Management - MarketBeat
Halozyme Therapeutics (HALO): Valuation Check After FDA Win and Patent Court Victory - Yahoo Finance
Halozyme Therapeutics (HALO) Is Up 7.4% After New ENHANZE NSCLC Win And Patent InjunctionWhat's Changed - Yahoo Finance
Does Halozyme Still Offer Value After a 44.5% Surge and Strong DCF Upside? - Sahm
Is Halozyme Still Attractively Priced After Its Strong 2025 Share Price Rally? - Yahoo Finance
EBITDA per share of Halozyme Therapeutics, Inc. – TRADEGATE:RV7 - TradingView — Track All Markets
Halozyme Therapeutics (BIT:1HALO) Price Target Decreased by 13.37% to 59.51 - Nasdaq
Halozyme Therapeutics (MEX:HALO) EV-to-OCF : 13.06 (As of Dec. 23, 2025) - GuruFocus
Halozyme Therapeutics (STU:RV7) EV-to-OCF : 13.50 (As of Dec. 22, 2025) - GuruFocus
Why Halozyme Therapeutics (HALO) Is Up 8.3% After FDA Nod And Patent Win In Lung Cancer - Sahm
Why Halozyme Therapeutics Inc. stock remains undervalued2025 Price Momentum & AI Powered Market Trend Analysis - Улправда
Congress Asset Management Co. Cuts Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Is Halozyme Therapeutics Inc. (RV7) stock undervalued after correctionMarket Activity Recap & Fast Moving Stock Trade Plans - Улправда
(HALO) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Market Fear: Is Halozyme Therapeutics Inc. (RV7) stock undervalued after correctionJuly 2025 Opening Moves & Low Volatility Stock Suggestions - ulpravda.ru
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) COO Sells 4,263 Shares of Stock - MarketBeat
HALO (Halozyme Therapeutics) EV-to-OCF : 14.29 (As of Dec. 20, 2025) - GuruFocus
COO Caudill Acquires 5,063 Of Halozyme Therapeutics Inc [HALO] - TradingView — Track All Markets
HC Wainwright & Co. Reiterates Halozyme Therapeutics (HALO) Buy Recommendation - Nasdaq
Is Halozyme Therapeutics Inc. stock vulnerable to regulatory risksWeekly Stock Summary & Community Trade Idea Sharing - Улправда
Breakouts Watch: Why Halozyme Therapeutics Inc. stock could see breakout soonJuly 2025 Levels & Weekly Breakout Opportunity Watchlist - Улправда
Halozyme Therapeutics Stock (HALO) Opinions on FDA Approval and Legal Win - Quiver Quantitative
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance
Halozyme Therapeutics' (HALO) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
HALO Analyst Rating: HC Wainwright & Co. Reiterates Buy Rating | - GuruFocus
Halozyme Therapeutics receives composite rating upgrade - MSN
Why Halozyme Therapeutics Inc. (RV7) stock is a must watch tickerPortfolio Return Report & AI Optimized Trading Strategy Guides - DonanımHaber
FDA approves Halozyme’s RYBREVANT FASPRO for EGFR-mutated lung cancer - Investing.com Nigeria
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer - PR Newswire
Where is Halozyme Therapeutics (HALO) Headed According to Analysts? - MSN
Bench International Announces Appointment of Jim Lang to the Board of Directors of Halozyme Therapeutics - StreetInsider
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B - Benzinga
Halozyme Therapeutics (HALO): A Fresh Look at Valuation After Board Appointment of Dealmaker Jim Lang - Sahm
Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade) - Seeking Alpha
Halozyme Therapeutics, Inc. $HALO Shares Bought by HRT Financial LP - MarketBeat
Halozyme Therapeutics Inc (HALO) 財務データ
収益
当期純利益
現金流量
EPS
Halozyme Therapeutics Inc (HALO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Caudill Cortney | SVP, CHIEF OPERATING OFFICER |
Nov 01 '25 |
Sale |
65.19 |
4,263 |
277,905 |
12,737 |
| Connaughton Bernadette | Director |
Dec 01 '25 |
Sale |
71.60 |
829 |
59,356 |
42,123 |
| Torley Helen | PRESIDENT AND CEO |
Dec 01 '25 |
Option Exercise |
8.11 |
16,569 |
134,375 |
725,288 |
| Torley Helen | PRESIDENT AND CEO |
Dec 01 '25 |
Sale |
68.92 |
16,569 |
1,141,925 |
708,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 10 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 11 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 12 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 12 '25 |
Sale |
70.55 |
20,000 |
1,410,990 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 11 '25 |
Sale |
69.13 |
20,000 |
1,382,600 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 10 '25 |
Sale |
68.72 |
20,000 |
1,374,339 |
733,719 |
0.57%
大文字化:
|
ボリューム (24 時間):